GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Inventories, Raw Materials & Components

Benevolent AI (Benevolent AI) Inventories, Raw Materials & Components : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Inventories, Raw Materials & Components?

Benevolent AI's inventories, raw materials & components for the quarter that ended in Dec. 2023 was $0.00 Mil.


Benevolent AI Inventories, Raw Materials & Components Historical Data

The historical data trend for Benevolent AI's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Inventories, Raw Materials & Components Chart

Benevolent AI Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
Get a 7-Day Free Trial - - - - -

Benevolent AI Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only - - - - -

Benevolent AI Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Benevolent AI (Benevolent AI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Inventories, Raw Materials & Components
Comparable Companies
Traded in Other Exchanges
Address
4-8 Maple Street, London, GBR, W1T 5HD
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.